# EDGAR Filing Document

**Accession Number:** 0001875091
**File Stem:** 0001213900-25-077513
**Filing Date:** 2025-8
**Character Count:** 32865
**Document Hash:** c41ea0c6e637a8df534e1be01922d4a4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-077513.hdr.sgml**: 20250815

**ACCESSION NUMBER**: 0001213900-25-077513

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20250815

**DATE AS OF CHANGE**: 20250815

**EFFECTIVENESS DATE**: 20250815

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NeuroSense Therapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001875091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289658
- **FILM NUMBER:** 251225255

**BUSINESS ADDRESS:**
- **STREET 1:** 11 HAMENOFIM ST.
- **STREET 2:** BUILDING B
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 4672562
- **BUSINESS PHONE:** 972-9-9531142

**MAIL ADDRESS:**
- **STREET 1:** 11 HAMENOFIM ST.
- **STREET 2:** BUILDING B
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 4672562

Registration No. ______________

As filed with the Securities and Exchange Commission on August 15, 2025

**UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> WASHINGTON, DC 20549

**FORM S-8**

**REGISTRATION STATEMENT<br> UNDER<br> THE SECURITIES ACT OF 1933**

**NeuroSense Therapeutics Ltd.**<br> (Exact name of registrant as specified in its charter)

<u>Israel</u> <u>Not Applicable</u> <br> (State or other jurisdiction of <br> incorporation or organization) (I.R.S. Employer <br> Identification No.)

**11 HaMenofim Street, Building B<br> Herzliya 4672562, Israel**

(Address of Principal Executive Offices) (Zip Code)<br>**NeuroSense Therapeutics Ltd. 2018 Employee Share Incentive Plan**

(Full title of the plan)

**Cogency Global Inc.<br> 122 East 42<sup>nd</sup> Street,<br> 18<sup>th</sup> Floor, New York, NY 10168<br> (212) 947-7200**

(Name and address of agent for service)

(Telephone number, including area code, of agent for service)<br>*Copies to:*

---

| | |
|:---|:---|
| Robert L. Grossman, Esq.<br> Gary Emmanuel, Esq.<br> David Huberman, Esq.<br> Greenberg Traurig, P.A.<br> One Azrieli Center<br> Round Tower, 30<sup>th</sup> Floor<br> 132 Menachem Begin Rd<br> Tel Aviv, Israel 6701101<br> +1 212 801 9337 | Perry Wildes<br> Ephraim Friedman.<br> Goldfarb Gross<br> Seligman & Co.<br> One Azrieli Center<br> Tel Aviv 6702100, Israel<br> +972 (3) 607-4444 |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐ Accelerated Filer ☐ <br> Non-Accelerated Filer ☒ Smaller reporting company ☐ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**STATEMENT PURSUANT TO GENERAL INSTRUCTION E** 

**OF FORM S-8**

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (this "<u>Registration Statement</u>") registers an additional 4,359,910 ordinary shares, no par value per share, of NeuroSense Therapeutics Ltd. (the "<u>Company</u>"), which may be issued under the NeuroSense Therapeutics Ltd. 2018 Employee Share Incentive Plan (the "<u>Plan</u>").

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

ITEM 1. PLAN INFORMATION. \*

ITEM 2. REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION. \*

\* Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this registration statement in accordance with Rule 428 under the Securities Act of 1933, as amended, or the Securities Act, and the Introductory Note to Part I of Form S-8.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

The following documents filed with or furnished to the Securities and Exchange Commission (the "<u>Commission</u>") by the Company are incorporated herein by reference and made a part hereof:

(a) the Company's Annual Report on [Form 20-F](http://www.sec.gov/Archives/edgar/data/1875091/000121390025029464/ea0237295-20f_neuro.htm) for the year ended December 31, 2024, filed with the Commission on April 7, 2025;

(b) the Company's reports on Form 6-K furnished to the Commission on [January 6, 2025](http://www.sec.gov/Archives/edgar/data/1875091/000121390025000994/ea0226872-6k_neuro.htm) , [February 19, 2025](http://www.sec.gov/Archives/edgar/data/1875091/000121390025015074/ea0231535-6k_neurosense.htm) , [March 19, 2025](http://www.sec.gov/Archives/edgar/data/1875091/000121390025024815/ea0234951-6k_neurosense.htm) , [March 27, 2025](http://www.sec.gov/Archives/edgar/data/1875091/000101376225002993/ea0235893-6k_neurosense.htm) , [April 7, 2025](http://www.sec.gov/Archives/edgar/data/1875091/000121390025029491/ea0237424-6k_neuro.htm) , [May 7, 2025](http://www.sec.gov/Archives/edgar/data/1875091/000121390025040433/ea0241207-6k_neurosense.htm) , [June 26, 2025](http://www.sec.gov/Archives/edgar/data/1875091/000121390025058086/ea0247095-6k_neurosense.htm) , [July 10, 2025](http://www.sec.gov/Archives/edgar/data/1875091/000121390025062549/ea0248532-6k_neurosense.htm) , and [August 1, 2025](http://www.sec.gov/Archives/edgar/data/1875091/000121390025070315/ea0250843-6k_neurosense.htm) ; and

(c) the description of the Registrant's ordinary shares contained in the Registrant's registration statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1875091/000121390021060442/ea150948-8a12b_neurosense.htm) (File No. 001-41084), filed by the Registrant with the SEC under Section 12(b) of the Securities and Exchange Act, as amended (the "Exchange Act") on November 18, 2021 including any amendments or reports filed for the purpose of updating such description.

All documents or reports subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and to the extent designated therein, certain reports on Form 6-K, furnished by the Company, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities offered hereby then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents or reports. Any statement in a document or report incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document or report which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

ITEM 4. DESCRIPTION OF SECURITIES

Not applicable.

ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

Not applicable.

ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

*Exemption, Insurance, and Indemnification of Directors and Officers*

Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision. A company may not exculpate in advance a director from liability arising from a breach of his or her duty of care in connection with a prohibited dividend or distribution to shareholders.

As permitted under the Companies Law, our amended and restated articles of association provide that we may indemnify an office holder in respect of the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either in advance of an event or following an event:

● a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator's decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company's activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;

● reasonable litigation expenses, including reasonable attorneys' fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding, (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent or (iii) in connection with a monetary sanction;

● reasonable litigation expenses, including attorneys' fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted or (iii) in a criminal indictment for which the office holder was convicted of an offense that does not require proof of criminal intent;

● expenses he or she incurs as a result of administrative proceedings that may be instituted against him or her under Israeli securities laws, if applicable, and payments made to injured persons under specific circumstances thereunder; and

● any other matter in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder in the company.

As permitted under the Companies Law, our amended and restated articles of association provide that we may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder:

● a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;

● a breach of duty of care to the company or to another person, to the extent such a breach arises out of the negligent conduct of the office holder;

● a monetary liability imposed on the office holder in favor of a third party;

● expenses he or she incurs as a result of administrative proceedings that may be instituted against him or her under the Israeli securities laws if applicable, and payments made to injured persons under specific circumstances thereunder; and

● any other matter in respect of which it is permitted or will be permitted under applicable law to insure the liability of an office holder in the company.

Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:

● a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;

● a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;

● an act or omission committed with intent to derive illegal personal benefit; or

● a fine or forfeit levied against the office holder.

Under the Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which controlling shareholders have a personal interest, also by the shareholders.

Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. Our office holders are currently covered by a directors' and officers' liability insurance policy. As of the date of this prospectus, no claims for directors' and officers' liability insurance have been filed under this policy and we are not aware of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which indemnification is sought.

We have entered into agreements with each of our current office holders exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law, including, with respect to liabilities resulting from this offering, to the extent that these liabilities are not covered by insurance. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable by the board of directors based on our activities. The maximum aggregate amount of indemnification that we may pay to our office holders based on such indemnification agreement is the greater of (i) an amount equal to 25% of our shareholders' equity on a consolidated basis, based on our most recent financial statements made publicly available before the date on which the indemnity payment is made, and (ii) $25 million. Such indemnification amounts are in addition to any insurance amounts. These indemnification agreements supersede all previous letters of indemnification that we have provided to him or her in the past, if any. However, in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable

ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED

Not applicable.

ITEM 8. EXHIBITS.

See Exhibit Index following the signature page.

ITEM 9. UNDERTAKINGS

---

| | | |
|:---|:---|:---|
| (a) | The undersigned Registrant hereby undertakes: | The undersigned Registrant hereby undertakes: |
|  | (1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
|  | (i) | to include any prospectus required by Section 10(a)(3) of the Securities Act; |
|  | (ii) | to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and |
|  | (iii) | to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; |

---

*provided, however,* that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement;

---

| | | |
|:---|:---|:---|
|  | (2) | that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof. |
|  | (3) | to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
| (b) | The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof. | The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof. |
| (c) | Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. | Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Herzliya, Israel, on August 15, 2025.

---

| | |
|:---|:---|
| **NEUROSENSE THERAPEUTICS LTD.** | **NEUROSENSE THERAPEUTICS LTD.** |
| By: | /s/ Or Eisenberg |
| Name: | Or Eisenberg |
| Title: | Chief Financial Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, each director and officer whose signature appears below constitutes and appoints, Mr. Alon Ben-Noon and Mr. Or Eisenberg, and each of them, individually, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, to sign in any and all capacities any and all amendments or post-effective amendments to this registration statement on Form S-8, and to sign any and all additional registration statements relating to the same offering of securities of the Registration Statement that are filed pursuant to Rule 462(b) of the Securities Act, and to file the same with all exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, granting such attorney-in-fact and agent full power and authority to do all such other acts and execute all such other documents as he may deem necessary or desirable in connection with the foregoing, as fully as the undersigned may or could do in person, hereby ratifying and confirming all that such attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this registration statement has been signed below by the following persons on the dates and in the capacities indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** |  |
| /s/ Mark Leuchtenberger | Chairman of the Board of Directors | August 15, 2025 |
| Mark Leuchtenberger |  |  |
| /s/ Alon Ben-Noon | Chief Executive Officer and Director | August 15, 2025 |
| Alon Ben-Noon | (Principal Executive Officer and Director) |  |
| /s/ Or Eisenberg | Chief Financial Officer (Principal Financial Officer | August 15, 2025 |
| Or Eisenberg | and Principal Accounting Officer) |  |
| /s/ Revital Mandil-Levin | Director | August 15, 2025 |
| Revital Mandil-Levin |  |  |
| /s/ Cary Claiborne | External Director | August 15, 2025 |
| Cary Claiborne |  |  |
| /s/ Christine Pellizzari | External Director | August 15, 2025 |
| Christine Pellizzari |  |  |

---

---

| | | |
|:---|:---|:---|
| /s/ Roy Golan | Director | August 15, 2025 |
| Roy Golan |  |  |

---

**Signature of authorized representative in the United States**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant's duly authorized representative has signed this Registration Statement on Form S-8 on this 15<sup>th</sup> day of August, 2025.

---

| | |
|:---|:---|
| Authorized U.S. Representative - COGENCY GLOBAL INC. | Authorized U.S. Representative - COGENCY GLOBAL INC. |
| By: | /s/ Colleen A. De Vries |
| Name: | Colleen A. De Vries |
| Title: | Sr. Vice-President on behalf of<br> Cogency Global Inc. |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| 3.1 | [Amended and Restated Articles of Association (incorporated by reference to Exhibit 1.1 to the Annual Report on Form 20-F filed with the SEC on April 7, 2025).](http://www.sec.gov/Archives/edgar/data/1875091/000121390025029464/ea023729501ex1-1_neuro.htm) |
| 4.1 | [Registrant's Specimen Certificate for Ordinary Shares (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form F-1/A filed with the SEC on December 6, 2021)](http://www.sec.gov/Archives/edgar/data/1875091/000121390021058163/ff12021a2ex4-4_neurosense.htm). |
| <br> 4.2 | <br> [NeuroSense Therapeutics Ltd. 2018 Employee Share Incentive Plan (incorporated by reference to Exhibit 4.2 to the Annual Report on Form 20-F filed with the SEC on April 7, 2025).](http://www.sec.gov/Archives/edgar/data/1875091/000121390025029464/ea023729501ex4-2_neuro.htm) |
| 5.1\* | [Opinion of Goldfarb Gross Seligman & Co.](ea025262201ex5-1_neurosense.htm) |
| 23.1\* | [Consent of Goldfarb Gross Seligman & Co. (included in Exhibit 5.1).](ea025262201ex5-1_neurosense.htm) |
| 23.2\* | [Consent of Somekh Chaikin (Member firm of KPMG International), Independent Registered Public Accounting Firm.](ea025262201ex23-2_neurosense.htm) |
| 24.1\* | [Power of Attorney (included on signature page).](#a_001) |
| 107\* | [Filing Fee Table](ea025262201ex-fee_neurosense.htm) |

---

\* Filed herewith.

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

August 15, 2025

NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B<br> Herzliya 4672562, Israel

Ladies and Gentlemen:

We refer to the Registration Statement on Form S-8 (the "Registration Statement") to be filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "Act"), on behalf of NeuroSense Therapeutics Ltd. (the "Company"), relating to 4,359,910 of the Company's ordinary shares, no par value per share (the "Plan Shares"), issuable under the NeuroSense Therapeutics Ltd. 2018 Employee Share Incentive Plan (the "Plan").

We are members of the Israel Bar and we express no opinion as to any matter relating to the laws of any jurisdiction other than the laws of Israel.

In connection with this opinion, we have examined such corporate records, other documents, and such questions of Israeli law as we have considered necessary or appropriate. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of documents submitted to us as certified or photostatic copies, the authenticity of the originals of such copies, as to matters of fact, the accuracy of all statements and representations made by officers of the Company and the due constitution of the Board of Directors of the Company. We have also assumed that each individual grant under the Plan that will be made after the date hereof will be duly authorized by all necessary corporate action.

Based on the foregoing and subject to the qualifications stated herein, we advise you that in our opinion, the Plan Shares being registered pursuant to the Registration Statement, when issued and paid for pursuant to the terms of the Plan, pursuant to agreements with respect to the 2018 Plan, and, as the case may be, pursuant to the terms of the awards that may be granted under the 2018 Plan, will be duly authorized, validly issued, fully paid and non-assessable.

This opinion is rendered as of the date hereof, and we undertake no obligation to advise you of any changes in applicable law or any other matters that may come to our attention after the date hereof that may affect this opinion.

![](ex5-1_002.jpg)

![](ex5-1_003.jpg)

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. This consent is not to be construed as an admission that we are a person whose consent is required to be filed with the Registration Statement under the provisions of the Act.

---

| |
|:---|
| Sincerely, |
| /s/ Goldfarb Gross Seligman & Co. |

---

## Exhibit 23.2

**Exhibit 23.2**

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated April 7, 2025, with respect to the consolidated financial statements of NeuroSense Therapeutics Ltd., incorporated herein by reference.

/s/ Somekh Chaikin

Somekh Chaikin

Member Firm of KPMG International

Tel Aviv, Israel

August 14, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**NEUROSENSE THERAPEUTICS LTD.**

**Table 1: Newly Registered and Carry Forward Securities**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Line Item Type** | **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* |
| Fees to be Paid | Equity | Ordinary shares, no par value per share | (1) | Other | 3210782 | $1.2750 | $4093747.00 | 0.0001531 | $626.75 |
| Fees to be Paid | Equity | Ordinary shares, no par value per share | (2) | Other | 1129128 | 2.21 | 2495373.00 | 0.0001531 | 382.05 |
| Fees to be Paid | Equity | Ordinary shares, no par value per share | (3) | Other | 20000 | $1.2750 | $25500.00 | 0.0001531 | $3.90 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $6614620.00 |  | 1012.70 |
| Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: |  |  |  |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $1012.70 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional ordinary shares, no par value per share, of the Registrant ("Ordinary Shares") that become issuable under the NeuroSense Therapeutics Ltd. 2018 Share Incentive Plan (the "Plan") by reason of any share dividend, share split, recapitalization or similar transaction. Represents the number of additional Ordinary Shares reserved for future issuance under the Plan. Estimated solely for purposes of calculating the registration fee pursuant to Rules 457(c) under the Securities Act and based on the average of the high and low prices of the Ordinary Shares as reported on The Nasdaq Capital Market on August 8, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional ordinary shares, no par value per share, of the Registrant ("Ordinary Shares") that become issuable under the NeuroSense Therapeutics Ltd. 2018 Share Incentive Plan (the "Plan") by reason of any share dividend, share split, recapitalization or similar transaction. Represents Ordinary Shares issuable upon exercise of outstanding options with fixed exercise prices under the Plan, with a weighted average exercise price of $2.21 per Ordinary Share. Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(h) under the Securities Act and based on the exercise price at which such options may be exercised.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional ordinary shares, no par value per share, of the Registrant ("Ordinary Shares") that become issuable under the NeuroSense Therapeutics Ltd. 2018 Share Incentive Plan (the "Plan") by reason of any share dividend, share split, recapitalization or similar transaction. Estimated solely for purposes of calculating the registration fee pursuant to Rules 457(c) under the Securities Act and based on the average of the high and low prices of the Ordinary Shares as reported on The Nasdaq Capital Market on August 8, 2025. Represents Ordinary Shares issuable upon the vesting and settlement of outstanding restricted share units granted under the Plan.